J. Biochem, 1989, Vol. 106, No. 1 38-42
© 1989 Japanese Biochemical Society
research-article |
Multiple Forms of Phospholipase A2 in Arthritic Synovial Fluid
*California Biotechnology Inc. 2450 Bayshore Parkway, Mt. View, CA 94043, U.S.A
**The Wellesley Hospital, University of Toronto Toronto, Ontario, M4Y 1J3 Canada
1To whom correspondence should be addressed. Present address: Ideon Corporation, 515 Galveston Dr., Redwood City, CA 94063, U.S.A.
Phospholipase A2 (PLA2) has been purified to homogeneity from human arthritic synovial fluid. The activity resolved into multiple peaks by preparative HPLC. The most abundant peak (A) was present in synovial fluid from patients with rheumatoid arthritis, osteoar-thritis, and psoriatic arthritis. A second major peak (B) was variable and lower in relative abundance, but was distinguishable from peak A by its stimulated activity in the presence of either 0.5 M Tris or 0.1% sodium deoxycholate (DOC), in addition to its longer HPLC column retention time. Both peaks required Ca2+ and showed optimal activity in DOC/ phosphatidylcholine (PC) mixed micelle assays between pH 8.0 and 9.0. Both peaks showed higher activity with PC as substrate than with PI, however peak A exhibited higher activity with PE than PC. Upon preparative SDS-polyacrylamide gel electrophoresis, both peaks of PLA2 activity were resolved as proteins of approximately 14, 000 Da. The N-terminal sequence obtained from purified peak A material matched that of a recent similar isolate (Hara et al. (1988))
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. G. Hains, K.-L. Sung, A. Tseng, and K. W. Broady Functional Characteristics of a Phospholipase A2 Inhibitor from Notechis ater Serum J. Biol. Chem., January 14, 2000; 275(2): 983 - 991. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Scott, S. White, J. Browning, J. Rosa, M. Gelb, and P. Sigler Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate Science, November 15, 1991; 254(5034): 1007 - 1010. [Abstract] [PDF] |
||||

